Company news
Kissei Pharmaceutical Co., Ltd. news in 2018
Kissei Pharmaceutical Co., Ltd.'s news releases, calls and decks from 2018, newest first.
Announcement of in-licensing of technology related to a small molecule tyrosine kinase inhibitor fostamatinib
October 29, 2018
Kissei Pharmaceutical Announces Negative Topline Results from the additional phase III Clinical Trial evaluating "KPS-0373 (Development Code)" for the Treatment of Spinocerebellar Ataxia
May 30, 2018
Kissei Pharmaceutical Announces New President and COO
April 23, 2018
JR-131, a Long-Acting Erythropoiesis-Stimulating Agent, Demonstrates Equivalence in Phase III Study
January 17, 2018